<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003960</url>
  </required_header>
  <id_info>
    <org_study_id>J9828 CDR0000067159</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-98032006</secondary_id>
    <secondary_id>JHOC-J9828</secondary_id>
    <secondary_id>NCI-G99-1543</secondary_id>
    <nct_id>NCT00003960</nct_id>
  </id_info>
  <brief_title>Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Bone marrow transplantation may allow the doctor to give higher&#xD;
      doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus donor&#xD;
      bone marrow transplantation in treating patients who have hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the 1-year survival rate of patients with hematologic malignancies&#xD;
      after treatment with HLA-matched allogeneic bone marrow transplantation after high-dose&#xD;
      chemotherapy.&#xD;
&#xD;
      OUTLINE: Patients receive oral busulfan four times a day on days -8 to -5, cyclophosphamide&#xD;
      IV over 1 hour on days -4 to -1, and methylprednisolone IV over 1 hour every 12 hours on days&#xD;
      -2 to 0. CD34+ stem cell augmented donor bone marrow is infused on day 0. Methylprednisolone&#xD;
      is administered IV over 1 hour on days 5-16, and then tapered. Patients are followed every 6&#xD;
      months for 1 year and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">September 2001</completion_date>
  <primary_completion_date type="Actual">September 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of any of the following: Chronic myelogenous leukemia&#xD;
        (CML) in first chronic phase Myelodysplastic syndrome Refractory anemia with excess blasts&#xD;
        (RAEB) RAEB in transformation Secondary leukemias untreated or in complete remission 1&#xD;
        (CR1) Acute myeloid leukemia in complete remission 2 (CR2) Acute lymphocytic leukemia (ALL)&#xD;
        in CR2 High-risk acute leukemia in CR1 Ph+ ALL in CR1 or consolidation after induction&#xD;
        chemotherapy Must qualify for allogeneic bone marrow transplantation (BMT) No HLA-matched,&#xD;
        sibling donor for BMT available No current CNS disease No history of more than 2 episodes&#xD;
        of active CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 19 to 55 Performance status: ECOG 0 or 1 Life expectancy: Not&#xD;
        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2 mg/dL Renal:&#xD;
        Creatinine no greater than 2 mg/dL Cardiovascular: LVEF at least 45% No active congestive&#xD;
        heart failure, arrhythmia, or angina pectoris No myocardial infarction within the past 12&#xD;
        months Pulmonary: FEV1 and FVC at least 50% predicted (75% predicted if received prior&#xD;
        thoracic or mantle radiotherapy) Other: No active serious infection (e.g., mucormycosis,&#xD;
        uncontrolled aspergillosis, or tuberculosis) HIV negative Not pregnant Fertile patients&#xD;
        must use effective contraception No concurrent debilitating medical or psychiatric illness&#xD;
        that would preclude compliance No prior malignancy except curatively treated skin cancer or&#xD;
        carcinoma of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior autologous&#xD;
        or allogeneic bone marrow transplantation No prior transfusions from donor Chemotherapy:&#xD;
        See Disease Characteristics Endocrine therapy: Not specified Radiotherapy: Not specified&#xD;
        Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul V. O'Donnell, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Treatment and Research</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2004</study_first_posted>
  <last_update_submitted>May 1, 2014</last_update_submitted>
  <last_update_submitted_qc>May 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2014</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

